The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | HMAs and venetoclax in MDS following VERONA: lessons from a negative Phase III trial
In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the role of hypomethylating agents (HMAs) and venetoclax combinations in higher-risk myelodysplastic syndromes (HR-MDS). He notes that despite negative results from the Phase III VERONA trial (NCT04401748), real-world data suggest that this combination may benefit certain patient subsets. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
